Sitagliptin/Metformin Merck 50 mg/850 mg film-coated tablets Malta - English - Medicines Authority

sitagliptin/metformin merck 50 mg/850 mg film-coated tablets

merck healthcare kgaa frankfurter strasse 250, 64293 darmstadt, germany - sitagliptin, metformin hydrochloride - film-coated tablet - metformin hydrochloride 850 mg sitagliptin 50 mg - drugs used in diabetes

SITAGLIPTN PCOR sitagliptin 50 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

sitagliptn pcor sitagliptin 50 mg film-coated tablet bottle

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 54.5 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; sodium stearylfumarate; povidone; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin pcor is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Sitagliptin / Metformin hydrochloride Accord European Union - English - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - drugs used in diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.it is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist.it is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

SITAGLIPTIN/METFORMIN SANDOZ XR 100/1000 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 100 mg/1000 mg extended release tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

sitagliptin/metformin sandoz xr 100/1000 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 100 mg/1000 mg extended release tablet bottle

sandoz pty ltd - sitagliptin hydrochloride monohydrate, quantity: 113.37 mg (equivalent: sitagliptin, qty 100 mg); metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: povidone; hypromellose; hyprolose; titanium dioxide; purified talc; macrogol 3350; propyl gallate; sodium stearylfumarate; indigo carmine aluminium lake; colloidal anhydrous silica - sitagliptin/metformin sandoz xr (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see section 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

SITAGLIPTIN/METFORMIN SANDOZ XR 50/1000 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/1000 mg extended release tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

sitagliptin/metformin sandoz xr 50/1000 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/1000 mg extended release tablet bottle

sandoz pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.685 mg (equivalent: sitagliptin, qty 50 mg); metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: propyl gallate; hyprolose; povidone; indigo carmine aluminium lake; purified talc; iron oxide yellow; colloidal anhydrous silica; sodium stearylfumarate; hypromellose; macrogol 3350; titanium dioxide - sitagliptin/metformin sandoz xr (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see section 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

PHARMACOR SITAGLIPTIN sitagliptin 100 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor sitagliptin sitagliptin 100 mg film-coated tablet blister pack

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 109 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; sodium stearylfumarate; povidone; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - pharmacor sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

PHARMACOR SITAGLIPTIN sitagliptin 100 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor sitagliptin sitagliptin 100 mg film-coated tablet bottle

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 109 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: sodium stearylfumarate; magnesium stearate; povidone; croscarmellose sodium; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - pharmacor sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

SITAGLIPTIN MAPLE sitagliptin (as hydrochloride monohydrate) 50 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sitagliptin maple sitagliptin (as hydrochloride monohydrate) 50 mg tablet blister pack

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - sitagliptin hydrochloride monohydrate is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin

SITAGLIPTIN MYLAN sitagliptin (as hydrochloride monohydrate) 50 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sitagliptin mylan sitagliptin (as hydrochloride monohydrate) 50 mg tablet blister pack

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - sitagliptin hydrochloride monohydrate is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin

SITAGLIPTIN MAPLE sitagliptin (as hydrochloride monohydrate) 100 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sitagliptin maple sitagliptin (as hydrochloride monohydrate) 100 mg tablet blister pack

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 113.376 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin hydrochloride monohydrate is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin